Matthew Perraton

Good morning, and thank you for joining us today. I'm Matthew Perraton, Investor Relations Manager at Theralase Technologies, Inc., and it's my pleasure to welcome all our shareholders and stakeholders to our 2025 annual financial statements conference call. We appreciate your ongoing support as Theralase executes on its strategic objectives, marking a pivotal phase of our transformation from preclinical research through clinical development to commercialization.

Before we begin, I would like to remind everyone that today's presentation may contain forward-looking statements as defined under applicable Canadian securities laws. Participants should not unduly rely on these forward-looking statements. They are not a guarantee of future performance, and there could be no assurance that they will prove accurate in the future. These forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause actual results or future events to differ materially. Although the forward-looking statements made today are based on what management believes to be reasonable assumptions, the company cannot guarantee investors that actual results will align with these expectations.

All forward-looking statements are made as of today's date and are subject to change without notice. Except as required by law, the company assumes no obligation to update them or revise them. This call will be posted on our corporate website in due course. Our Phase II bladder cancer clinical study has exceeded our target enrollment of 90 patients, enrolling 91 patients in total, although additional patients may be enrolled in 2026, in our Canadian clinical study sites. Of the 91 patients, 82 have completed the study with the remaining 9 patients currently on study. Theralase plans to file a new drug application under rolling